D
Avanos Medical, Inc.
AVNS
$13.27
-$0.76-5.42%
D
Sell
3/31/2025Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to D- from E+ on 3/31/2025 due to an increase in the volatility index.
Avanos Medical, Inc. (AVNS) was upgraded to D- from E+ on 3/31/2025 due to an increase in the volatility index.
E
Sell
3/14/2025Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to E+ from D- on 3/14/2025 due to a decline in the volatility index and total return index.
Avanos Medical, Inc. (AVNS) was downgraded to E+ from D- on 3/14/2025 due to a decline in the volatility index and total return index.
D
Sell
3/3/2025Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to D- from D+ on 3/3/2025 due to a significant decline in the growth index, efficiency index and total return index. Earnings per share declined from $0.0857 to -$8.639, net income declined 9,339.53% from $4.3M to -$397.3M, and EBIT declined 46.67% from $16.5M to $8.8M.
Avanos Medical, Inc. (AVNS) was downgraded to D- from D+ on 3/3/2025 due to a significant decline in the growth index, efficiency index and total return index. Earnings per share declined from $0.0857 to -$8.639, net income declined 9,339.53% from $4.3M to -$397.3M, and EBIT declined 46.67% from $16.5M to $8.8M.
D
Sell
10/18/2024Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to D+ from C- on 10/18/2024 due to a decline in the volatility index.
Avanos Medical, Inc. (AVNS) was downgraded to D+ from C- on 10/18/2024 due to a decline in the volatility index.
C
Hold
10/3/2024Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to C- from D+ on 10/3/2024 due to an increase in the total return index and volatility index.
Avanos Medical, Inc. (AVNS) was upgraded to C- from D+ on 10/3/2024 due to an increase in the total return index and volatility index.
D
Sell
8/1/2024Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to D+ from D on 8/1/2024 due to a significant increase in the growth index, volatility index and efficiency index. Operating cash flow increased 447.5% from -$8M to $27.8M, net income increased 300% from -$900 to $1.8M, and earnings per share increased from -$0.02 to $0.036.
Avanos Medical, Inc. (AVNS) was upgraded to D+ from D on 8/1/2024 due to a significant increase in the growth index, volatility index and efficiency index. Operating cash flow increased 447.5% from -$8M to $27.8M, net income increased 300% from -$900 to $1.8M, and earnings per share increased from -$0.02 to $0.036.
D
Sell
11/3/2023Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to D from E+ on 11/3/2023 due to a substantial increase in the efficiency index, total return index and volatility index. Net income increased 94.57% from -$68.1M to -$3.7M, and total capital increased 2.69% from $1.49B to $1.53B.
Avanos Medical, Inc. (AVNS) was upgraded to D from E+ on 11/3/2023 due to a substantial increase in the efficiency index, total return index and volatility index. Net income increased 94.57% from -$68.1M to -$3.7M, and total capital increased 2.69% from $1.49B to $1.53B.
E
Sell
10/23/2023Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to E+ from D- on 10/23/2023 due to a decline in the total return index and volatility index.
Avanos Medical, Inc. (AVNS) was downgraded to E+ from D- on 10/23/2023 due to a decline in the total return index and volatility index.
D
Sell
10/6/2023Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to D- from E+ on 10/6/2023 due to an increase in the volatility index.
Avanos Medical, Inc. (AVNS) was upgraded to D- from E+ on 10/6/2023 due to an increase in the volatility index.
E
Sell
9/20/2023Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to E+ from D- on 9/20/2023 due to a decline in the volatility index and total return index.
Avanos Medical, Inc. (AVNS) was downgraded to E+ from D- on 9/20/2023 due to a decline in the volatility index and total return index.
D
Sell
8/31/2023Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to D- from E+ on 8/31/2023 due to an increase in the volatility index and valuation index.
Avanos Medical, Inc. (AVNS) was upgraded to D- from E+ on 8/31/2023 due to an increase in the volatility index and valuation index.
E
Sell
8/15/2023Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to E+ from D- on 8/15/2023 due to a decline in the volatility index.
Avanos Medical, Inc. (AVNS) was downgraded to E+ from D- on 8/15/2023 due to a decline in the volatility index.
D
Sell
8/11/2023Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to D- from D on 8/11/2023 due to a significant decline in the valuation index, efficiency index and solvency index. Net income declined 13,520% from -$500 to -$68.1M, debt to equity increased from 0.17 to 0.18, and total capital declined 4.21% from $1.55B to $1.49B.
Avanos Medical, Inc. (AVNS) was downgraded to D- from D on 8/11/2023 due to a significant decline in the valuation index, efficiency index and solvency index. Net income declined 13,520% from -$500 to -$68.1M, debt to equity increased from 0.17 to 0.18, and total capital declined 4.21% from $1.55B to $1.49B.
D
Sell
8/4/2023Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to D from D+ on 8/4/2023 due to a decline in the efficiency index, total return index and volatility index.
Avanos Medical, Inc. (AVNS) was downgraded to D from D+ on 8/4/2023 due to a decline in the efficiency index, total return index and volatility index.
D
Sell
7/20/2023Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to D+ from D on 7/20/2023 due to an increase in the volatility index and valuation index.
Avanos Medical, Inc. (AVNS) was upgraded to D+ from D on 7/20/2023 due to an increase in the volatility index and valuation index.
D
Sell
7/3/2023Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to D from D+ on 7/3/2023 due to a decline in the volatility index, total return index and valuation index.
Avanos Medical, Inc. (AVNS) was downgraded to D from D+ on 7/3/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
5/11/2023Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to D+ from C- on 5/11/2023 due to a decline in the volatility index and total return index.
Avanos Medical, Inc. (AVNS) was downgraded to D+ from C- on 5/11/2023 due to a decline in the volatility index and total return index.
C
Hold
5/5/2023Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to C- from C on 5/5/2023 due to a significant decline in the growth index. Operating cash flow declined 120.18% from $33.7M to -$6.8M, earnings per share declined from $0.3593 to -$0.0107, and EBIT declined 62.17% from $30.4M to $11.5M.
Avanos Medical, Inc. (AVNS) was downgraded to C- from C on 5/5/2023 due to a significant decline in the growth index. Operating cash flow declined 120.18% from $33.7M to -$6.8M, earnings per share declined from $0.3593 to -$0.0107, and EBIT declined 62.17% from $30.4M to $11.5M.
C
Hold
1/20/2023Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to C from C- on 1/20/2023 due to an increase in the volatility index and total return index.
Avanos Medical, Inc. (AVNS) was upgraded to C from C- on 1/20/2023 due to an increase in the volatility index and total return index.
C
Hold
12/19/2022Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to C- from D+ on 12/19/2022 due to an increase in the total return index and volatility index.
Avanos Medical, Inc. (AVNS) was upgraded to C- from D+ on 12/19/2022 due to an increase in the total return index and volatility index.
D
Sell
11/4/2022Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to D+ from D on 11/4/2022 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 37.72% from $11.4M to $15.7M, earnings per share increased from $0.24 to $0.33, and operating cash flow increased 5.19% from $27M to $28.4M.
Avanos Medical, Inc. (AVNS) was upgraded to D+ from D on 11/4/2022 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 37.72% from $11.4M to $15.7M, earnings per share increased from $0.24 to $0.33, and operating cash flow increased 5.19% from $27M to $28.4M.
D
Sell
5/9/2022Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to D from D+ on 5/9/2022 due to a significant decline in the growth index, volatility index and solvency index. Operating cash flow declined 96.55% from $52.1M to $1.8M, debt to equity increased from 0.11 to 0.21, and earnings per share declined from $0.2075 to $0.12.
Avanos Medical, Inc. (AVNS) was downgraded to D from D+ on 5/9/2022 due to a significant decline in the growth index, volatility index and solvency index. Operating cash flow declined 96.55% from $52.1M to $1.8M, debt to equity increased from 0.11 to 0.21, and earnings per share declined from $0.2075 to $0.12.
D
Sell
4/20/2022Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to D+ from C- on 4/20/2022 due to a decline in the volatility index.
Avanos Medical, Inc. (AVNS) was downgraded to D+ from C- on 4/20/2022 due to a decline in the volatility index.
C
Hold
2/28/2022Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to C- from D on 2/28/2022 due to a significant increase in the growth index, efficiency index and solvency index. Net income increased 128.49% from -$35.1M to $10M, earnings per share increased from -$0.73 to $0.2075, and operating cash flow increased 124.57% from $23.2M to $52.1M.
Avanos Medical, Inc. (AVNS) was upgraded to C- from D on 2/28/2022 due to a significant increase in the growth index, efficiency index and solvency index. Net income increased 128.49% from -$35.1M to $10M, earnings per share increased from -$0.73 to $0.2075, and operating cash flow increased 124.57% from $23.2M to $52.1M.
D
Sell
5/26/2021Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to D from D+ on 5/26/2021 due to a decline in the volatility index and total return index.
Avanos Medical, Inc. (AVNS) was downgraded to D from D+ on 5/26/2021 due to a decline in the volatility index and total return index.
D
Sell
5/11/2021Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to D+ from D on 5/11/2021 due to an increase in the growth index, solvency index and valuation index. EBIT increased 806.25% from -$1.6M to $11.3M, earnings per share increased from -$0.9897 to -$0.16, and debt to equity declined from 0.16 to 0.15.
Avanos Medical, Inc. (AVNS) was upgraded to D+ from D on 5/11/2021 due to an increase in the growth index, solvency index and valuation index. EBIT increased 806.25% from -$1.6M to $11.3M, earnings per share increased from -$0.9897 to -$0.16, and debt to equity declined from 0.16 to 0.15.
D
Sell
3/26/2021Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to D from D+ on 3/26/2021 due to a decline in the total return index.
Avanos Medical, Inc. (AVNS) was downgraded to D from D+ on 3/26/2021 due to a decline in the total return index.
D
Sell
2/19/2021Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to D+ from C on 2/19/2021 due to a significant decline in the growth index, efficiency index and solvency index. Earnings per share declined from $0.4 to -$0.9897, net income declined 344.56% from $19.3M to -$47.2M, and EBIT declined 142.11% from $3.8M to -$1.6M.
Avanos Medical, Inc. (AVNS) was downgraded to D+ from C on 2/19/2021 due to a significant decline in the growth index, efficiency index and solvency index. Earnings per share declined from $0.4 to -$0.9897, net income declined 344.56% from $19.3M to -$47.2M, and EBIT declined 142.11% from $3.8M to -$1.6M.
C
Hold
2/12/2021Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to C from C- on 2/12/2021 due to a large increase in the total return index, solvency index and volatility index.
Avanos Medical, Inc. (AVNS) was upgraded to C from C- on 2/12/2021 due to a large increase in the total return index, solvency index and volatility index.
C
Hold
11/9/2020Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to C- from D on 11/9/2020 due to a significant increase in the growth index, volatility index and valuation index. Earnings per share increased from -$0.0628 to $0.4, EBIT increased 192.31% from $1.3M to $3.8M, and total revenue increased 13.44% from $163.7M to $185.7M.
Avanos Medical, Inc. (AVNS) was upgraded to C- from D on 11/9/2020 due to a significant increase in the growth index, volatility index and valuation index. Earnings per share increased from -$0.0628 to $0.4, EBIT increased 192.31% from $1.3M to $3.8M, and total revenue increased 13.44% from $163.7M to $185.7M.
D
Sell
8/13/2019Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to D from D+ on 8/13/2019 due to a noticeable decline in the efficiency index, volatility index and valuation index.
Avanos Medical, Inc. (AVNS) was downgraded to D from D+ on 8/13/2019 due to a noticeable decline in the efficiency index, volatility index and valuation index.
D
Sell
5/9/2019Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to D+ from C- on 5/9/2019 due to a major decline in the valuation index, growth index and efficiency index. Net income declined 822.73% from -$2.2M to -$20.3M, earnings per share declined from -$0.0495 to -$0.43, and EBIT declined 256.94% from $14.4M to -$22.6M.
Avanos Medical, Inc. (AVNS) was downgraded to D+ from C- on 5/9/2019 due to a major decline in the valuation index, growth index and efficiency index. Net income declined 822.73% from -$2.2M to -$20.3M, earnings per share declined from -$0.0495 to -$0.43, and EBIT declined 256.94% from $14.4M to -$22.6M.
C
Hold
4/25/2019Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to C- from C on 4/25/2019 due to a major decline in the valuation index, growth index and total return index. Earnings per share declined from $0.0888 to -$0.0495, and EBIT declined 8.86% from $15.8M to $14.4M.
Avanos Medical, Inc. (AVNS) was downgraded to C- from C on 4/25/2019 due to a major decline in the valuation index, growth index and total return index. Earnings per share declined from $0.0888 to -$0.0495, and EBIT declined 8.86% from $15.8M to $14.4M.
C
Hold
1/17/2019Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to C from C+ on 1/17/2019 due to a noticeable decline in the volatility index and total return index.
Avanos Medical, Inc. (AVNS) was downgraded to C from C+ on 1/17/2019 due to a noticeable decline in the volatility index and total return index.
C
Hold
12/10/2018Downgrade
Avanos Medical, Inc. (AVNS) was downgraded to C+ from B- on 12/10/2018 due to a major decline in the total return index and volatility index.
Avanos Medical, Inc. (AVNS) was downgraded to C+ from B- on 12/10/2018 due to a major decline in the total return index and volatility index.
B
Buy
11/8/2018Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to B- from C+ on 11/8/2018 due to a substantial increase in the efficiency index, growth index and solvency index. Operating cash flow increased 29.89% from -$96.7M to -$67.8M, EBIT increased 12.86% from $14M to $15.8M, and the quick ratio increased from 1.9 to 2.12.
Avanos Medical, Inc. (AVNS) was upgraded to B- from C+ on 11/8/2018 due to a substantial increase in the efficiency index, growth index and solvency index. Operating cash flow increased 29.89% from -$96.7M to -$67.8M, EBIT increased 12.86% from $14M to $15.8M, and the quick ratio increased from 1.9 to 2.12.
C
Hold
8/17/2018Upgraded
Avanos Medical, Inc. (AVNS) was upgraded to C+ from C on 8/17/2018 due to a substantial increase in the total return index, valuation index and volatility index.
Avanos Medical, Inc. (AVNS) was upgraded to C+ from C on 8/17/2018 due to a substantial increase in the total return index, valuation index and volatility index.
C
Hold
8/14/2017Upgraded
Halyard Health, Inc. (HYH) was upgraded to C from C- on 8/14/2017 due to an increase in the growth index, valuation index and volatility index. EBIT increased 33.84% from $26.3M to $35.2M, earnings per share increased from $0.27 to $0.36, and total revenue increased 0.91% from $395.6M to $399.2M.
Halyard Health, Inc. (HYH) was upgraded to C from C- on 8/14/2017 due to an increase in the growth index, valuation index and volatility index. EBIT increased 33.84% from $26.3M to $35.2M, earnings per share increased from $0.27 to $0.36, and total revenue increased 0.91% from $395.6M to $399.2M.
C
Hold
2/27/2017Downgrade
Halyard Health, Inc. (HYH) was downgraded to C- from C on 2/27/2017 due to a large decline in the growth index, valuation index and efficiency index. EBIT declined 19.69% from $25.9M to $20.8M, operating cash flow declined 10.02% from $49.9M to $44.9M, and total capital declined 0.56% from $1.69B to $1.68B.
Halyard Health, Inc. (HYH) was downgraded to C- from C on 2/27/2017 due to a large decline in the growth index, valuation index and efficiency index. EBIT declined 19.69% from $25.9M to $20.8M, operating cash flow declined 10.02% from $49.9M to $44.9M, and total capital declined 0.56% from $1.69B to $1.68B.
C
Hold
1/17/2017Upgraded
Halyard Health, Inc. (HYH) was upgraded to C from C- on 1/17/2017 due to an increase in the total return index and volatility index.
Halyard Health, Inc. (HYH) was upgraded to C from C- on 1/17/2017 due to an increase in the total return index and volatility index.
C
Hold
11/4/2016Upgraded
Halyard Health, Inc. (HYH) was upgraded to C- from D on 11/4/2016 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 40% from $6.5M to $9.1M, earnings per share increased from $0.1392 to $0.19, and EBIT increased 9.75% from $23.6M to $25.9M.
Halyard Health, Inc. (HYH) was upgraded to C- from D on 11/4/2016 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 40% from $6.5M to $9.1M, earnings per share increased from $0.1392 to $0.19, and EBIT increased 9.75% from $23.6M to $25.9M.
D
Sell
11/6/2015Downgrade
Halyard Health, Inc. (HYH) was downgraded to D from D+ on 11/6/2015 due to a major decline in the efficiency index, growth index and valuation index. Earnings per share declined from $0.17 to -$10.1, net income declined 5,981.25% from $8M to -$470.5M, and EBIT declined 35.29% from $22.1M to $14.3M.
Halyard Health, Inc. (HYH) was downgraded to D from D+ on 11/6/2015 due to a major decline in the efficiency index, growth index and valuation index. Earnings per share declined from $0.17 to -$10.1, net income declined 5,981.25% from $8M to -$470.5M, and EBIT declined 35.29% from $22.1M to $14.3M.
D
Sell
11/5/2015Downgrade
Halyard Health, Inc. (HYH) was downgraded to D+ from C- on 11/5/2015 due to a decline in the growth index.
Halyard Health, Inc. (HYH) was downgraded to D+ from C- on 11/5/2015 due to a decline in the growth index.
C
Hold
10/1/2015Upgraded
Halyard Health, Inc. (HYH) was upgraded to C- from D+ on 10/1/2015 due to an increase in the valuation index.
Halyard Health, Inc. (HYH) was upgraded to C- from D+ on 10/1/2015 due to an increase in the valuation index.
D
Sell
8/24/2015Downgrade
Halyard Health, Inc. (HYH) was downgraded to D+ from C- on 8/24/2015 due to a large decline in the total return index, growth index and volatility index. Earnings per share declined from $0.46 to $0.17, operating cash flow declined 59.7% from $39.7M to $16M, and EBIT declined 23.53% from $28.9M to $22.1M.
Halyard Health, Inc. (HYH) was downgraded to D+ from C- on 8/24/2015 due to a large decline in the total return index, growth index and volatility index. Earnings per share declined from $0.46 to $0.17, operating cash flow declined 59.7% from $39.7M to $16M, and EBIT declined 23.53% from $28.9M to $22.1M.
C
Hold
8/6/2015Downgrade
Halyard Health, Inc. (HYH) was downgraded to C- from C on 8/6/2015 due to a large decline in the volatility index, total return index and efficiency index. Net income declined 1,004.17% from -$2.4M to $21.7M.
Halyard Health, Inc. (HYH) was downgraded to C- from C on 8/6/2015 due to a large decline in the volatility index, total return index and efficiency index. Net income declined 1,004.17% from -$2.4M to $21.7M.
C
Hold
3/13/2015Upgraded
Halyard Health, Inc. (HYH) was upgraded to C from C- on 3/13/2015 due to a significant increase in the growth index, total return index and volatility index. Operating cash flow increased 72.03% from $23.6M to $40.6M, EBIT increased 39.89% from $18.8M to $26.3M, and total revenue increased 6.34% from $408.5M to $434.4M.
Halyard Health, Inc. (HYH) was upgraded to C from C- on 3/13/2015 due to a significant increase in the growth index, total return index and volatility index. Operating cash flow increased 72.03% from $23.6M to $40.6M, EBIT increased 39.89% from $18.8M to $26.3M, and total revenue increased 6.34% from $408.5M to $434.4M.
C
Hold
1/22/2015Upgraded
Halyard Health, Inc. (HYH) was upgraded to C- from D+ on 1/22/2015 due to a major increase in the total return index, volatility index and solvency index.
Halyard Health, Inc. (HYH) was upgraded to C- from D+ on 1/22/2015 due to a major increase in the total return index, volatility index and solvency index.
D
Sell
1/16/2015None
Avanos Medical, Inc. (AVNS) was downgraded to D+ from U on 01/16/2015.
Avanos Medical, Inc. (AVNS) was downgraded to D+ from U on 01/16/2015.
NYSE
04/04/2025 12:49PM Eastern
Quotes delayed
